Aptorum Group (APM) and DiamiR Biosciences said that DiamiR received a Clinical Laboratory Evaluation Program Test Approval for its APOE Genotyping test from the New York State Department of Health.

The test identifies genetic variants associated with risk for late-onset Alzheimer's disease and other neurological conditions. The two companies expect to close their merger in Q4.

Aptorum's stock more than tripled as intraday volume topped 309.7 million shares, compared with the daily average of almost 3.35 million.

Protagenic Therapeutics (PTIX) completed the first patient dosing in the multiple-dose portion of its Phase 1 trial of PT00114, an investigational therapy based on a brain hormone that regulates stress and emotional balance.

The company expects to complete dosing by the end of August, with topline safety data anticipated by the end of September.

The shares more than doubled as volume topped 147 million versus the daily average of almost 205,000.

Cato (CATO) shares surged 35% after the company reported an increase in fiscal Q2 earnings and revenue.

Volume topped 1.78 million versus the daily average of almost 38,000.

Price: 3.92, Change: +2.65, Percent Change: +208.58